GlassScriptPhysician profile
Chantal Maxene Lajeunesse
NPI 1376098731
$3,607.74
in general payments reported to CMS, 2019-2025
18 companies · $2,379 in 2025
The $2,379 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $157 · 2024: $1,072 · 2025: $2,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $638.08 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $633.14 | 2024-2025 | Auvelity |
| Abbvie INC. | $410.05 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $395.15 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $390.15 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $362.17 | 2024-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $196.07 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $169.39 | 2024-2025 | Ingrezza |
| Indivior INC. | $92.61 | 2023-2024 | Sublocade |
| Lundbeck LLC | $77.60 | 2025 | Rexulti |
| Bausch Health US, LLC | $50.40 | 2024-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $44.03 | 2025 | Trintellix |
| Tempus Ai, INC | $34.18 | 2024 | |
| Neos Therapeutics, LP | $30.95 | 2024-2025 | Adzenys Xr-Odt |
| Braeburn INC. | $26.30 | 2024 | Brixadi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.59 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $15.21 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chantal Lajeunesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.